Free Trial
NASDAQ:BCTX

Briacell Therap 6/13/2025 Earnings Report

Briacell Therap logo
$2.07 -0.04 (-1.90%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 0.00 (-0.24%)
As of 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Briacell Therap EPS Results

Actual EPS
-$1.64
Consensus EPS
-$1.76
Beat/Miss
Beat by +$0.12
One Year Ago EPS
N/A

Briacell Therap Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Briacell Therap Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Briacell Therap Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
BCTX BriaCell Therapeutics Corp. - Seeking Alpha
See More Briacell Therap Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email.

About Briacell Therap

Briacell Therap (NASDAQ:BCTX)eutics Corp. (NASDAQ: BCTX) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer. The company’s research centers on harnessing the patient’s immune system to recognize and eliminate tumor cells, with an emphasis on breast, prostate, lung and ovarian cancers. BriaCell’s proprietary platforms are designed to generate robust anti-tumor responses through the presentation of tumor-associated antigens alongside immune-modulating factors.

Bria-IMT, the company’s lead investigational therapy, comprises an allogeneic cell line engineered to express key antigens and cytokines to activate T-cell mediated tumor destruction. Delivered directly to patients, Bria-IMT is being evaluated in clinical trials to assess its safety and efficacy as a first-in-class immuno-oncology treatment. In parallel, Bria-OTS is under development as an off-the-shelf cell therapy, offering a scalable manufacturing model intended to broaden patient access without the delays associated with personalized therapies.

Headquartered in Vancouver, Canada, BriaCell operates a state-of-the-art manufacturing facility in Burlingame, California. The company’s clinical programs are conducted at leading cancer centers across North America, leveraging both internal capabilities and collaborative partnerships to support trial execution and future commercialization. BriaCell’s integrated infrastructure facilitates efficient production, quality control and regulatory compliance throughout the development process.

Founded in 1998, BriaCell has grown from early-stage research into a company with a diversified pipeline of immunotherapeutic candidates. Under the leadership of President and CEO Arash Samadi, the organization has strengthened its governance, expanded its R&D expertise and bolstered its management team with experienced professionals in oncology development, regulatory affairs and manufacturing. Together, they are committed to advancing transformative cancer treatments to patients worldwide.

View Briacell Therap Profile

More Earnings Resources from MarketBeat